StreetInsider.com News Articles

Kymera Therapeutics (KYMR) PT Raised to $140 at Mizuho

Thu, 16 Jul 2026 05:29:30 -0400

Mizuho analyst Joseph Catanzaro raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $140.00 (from $120.00) while maintaining a Outperform rating.

The analyst comments "Following an acceleration of KT-621's timelines in atopic dermatitis (AD), as well as recent strong KOL feedback on KT-621's potential profile that underscores its blockbuster opportunity, we raise our PT to $140 from $120. More specifically, KOLs believed that with a clean safety label KT-621 would see broad utilization even with an efficacy profile less competitive to biologics. However, KOLs see clear opportunity for biologic-like efficacy that in turn could position KT-621 to even displace Dupixent.

Kymera Therapeutics (KYMR) call put ratio 1 call to 3.3 puts with a focus on December 95 and 100 puts as share price down 8%

Mon, 13 Jul 2026 14:07:14 -0400

Kymera Therapeutics (NASDAQ: KYMR) 30-day option implied volatility is at 60; compared to its 52-week range of 45 to 156. Call put ratio 1 call to 3.3 puts with a focus on December 95 and 100 puts as share price down 8%.

Form 4 Kymera Therapeutics, For: Jul 07 Filed by: Mainolfi Nello

Tue, 07 Jul 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26743083.html

Form 4 Kymera Therapeutics, For: Jul 07 Filed by: Mainolfi Nello

Tue, 07 Jul 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26743083.html

Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello

Tue, 07 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260707/26741844.html

Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello

Tue, 07 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260707/26741844.html

Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program

Tue, 07 Jul 2026 07:00:49 -0400

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

Dr. Laws previously served as Senior Vice President, Head of Sanofi Integrated Launch & Commercialization Excellence. She also held roles at Sanofi as Vice President, Head of the Immunology & Inflammation Therapeutic Area, and Vice President, Head of the Dupilumab/Dupixent Development Program. Earlier in her career, she held positions at MDS Pharma and McKinsey & Company.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera

Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program

Tue, 07 Jul 2026 07:00:49 -0400

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera

Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program

Tue, 07 Jul 2026 07:00:49 -0400

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera

Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program

Tue, 07 Jul 2026 07:00:49 -0400

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera

Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program

Tue, 07 Jul 2026 07:00:49 -0400

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera

Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program

Tue, 07 Jul 2026 07:00:49 -0400

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader